Dr. Jason Fung Recap: His Take on Cancer Screening, Early Spread and Blood-Based Tests

The newest full video on Dr. Jason Fung's official YouTube channel, "The Future of Cancer Screening," was published on November 9, 2026 and runs about 15 minutes. Dr. Fung, a kidney specialist (nephrologist) and author best known for his writing on fasting and obesity, speaks to the camera alone. His main argument is that catching cancer before it spreads matters most for survival, that many of today's common screening tests do less than people assume, and that a newer kind of blood test that looks for tumor DNA could change how screening works. This is one doctor's opinion on a complex and actively debated topic, so treat it as a viewpoint to think about, not as guidance on which tests to get or skip.

This is an independent summary written by GNOUP. It is not affiliated with, sponsored by or endorsed by Dr. Fung, his channel, The Fasting Method, GRAIL or any company or test mentioned in the video. The views and claims described below belong to the speaker, not to GNOUP. This is general information only and is not medical advice. Please do not start, stop or skip any cancer screening based on this summary; decisions about screening depend on your age, health history and family history, so talk them through with a doctor or other qualified healthcare professional. The same goes for any change to diet, fasting or medication, especially if you have diabetes, take any medication, are pregnant or breastfeeding, are under 18, or have a history of an eating disorder. GNOUP has no connection to the books, tests, programs or other paid offers mentioned in or around the video and does not promote them.

Key health tips and takeaways

These are Dr. Fung's own ideas and explanations from the video, not instructions. GNOUP has not checked the studies or numbers he mentions.

• Stage at diagnosis is the big factor, he says. Dr. Fung explains that cancers are usually grouped into four stages: stages one and two are early disease, stage three means spread to nearby tissue such as lymph nodes, and stage four means spread to distant organs such as the lungs or liver. In his view, finding a cancer even one stage earlier can make a large difference in survival.
• Screening has downsides as well as benefits. He points out that screening can turn up findings that would never have caused harm, which can lead to extra biopsies and other invasive procedures. He argues that how invasive a test is should be weighed alongside how well it works.
• Most cancers are not found by screening today, according to him. He says only a minority of cancers are picked up through population screening (he cites about 6% in the UK and 14% in the US), that most show up once they cause symptoms, and that there are dozens of cancer types with no routine screening test at all.
• He thinks spread, not size, is what screening should look for. Drawing on ideas from his book, he argues that cancers can start shedding cells into the blood very early, before a tumor is visible on a scan, and that a test aimed at early spread makes more sense to him than one aimed at tumor size. Many cancer specialists see the biology in more nuanced terms.
• Cervical screening was left out of his critique. He notes that the review he discusses did not cover Pap smears and says that screening appears to be very effective.

Newsworthy insights

These are claims and opinions from the video. Some experts dispute them, GNOUP has not verified them, and the transcript does not include full references.

• A critical look at common screening tests. Dr. Fung describes a 2023 review in JAMA Internal Medicine that, he says, looked at randomized trials of mammograms, stool blood tests, colonoscopy and sigmoidoscopy, lung CT scans for smokers, and PSA tests for prostate cancer. In his reading, none clearly extended overall lifespan, with estimated life gained of about zero for mammograms and stool blood tests, roughly 37 days for the bowel scope tests and about 107 days for lung CT in smokers. Health agencies still recommend many of these screenings for specific groups, and how to interpret this kind of research is debated, so this is not a reason on its own to skip a recommended test.
• What a "liquid biopsy" is. He explains that newer tests look for tiny amounts of circulating tumor DNA (ctDNA) in a blood sample, and that a multi-cancer early detection (MCED) test tries to spot signals from many cancer types at once and suggest where in the body a cancer may be.
• His reading of a large trial of one such test. He discusses a randomized trial of about 140,000 people aged 50 to 77 testing GRAIL's Galleri blood test over three years. He says the main goal, a drop in combined stage three and stage four cancers, was not met, but that a pre-specified secondary analysis showed about 14% fewer stage four cancers and more stage three cancers, which he reads as some cancers being caught one stage earlier. He also says the reduction in stage four cases grew over the screening years (about 9%, 24% and 26% in his figures). These are his descriptions of the results, not GNOUP's.
• Survival gaps between stage three and four. For bladder, liver and bile duct, and esophageal cancers, he cites historical survival figures that he says are roughly four to six times better at stage three than at stage four, and notes there is currently no routine early screening for those cancers.
• Claims about approval and his view of the future. He says the test has been approved by the US Food and Drug Administration and is available in the US and Canada, that who pays for it is still an open question, and that he has no ownership stake in the company. He calls this kind of test the future of cancer screening. GNOUP has not verified the approval status, coverage or availability, and like any screening test, a blood test like this can miss cancers or flag ones that are not there. Whether any screening test is right for you is a question for your doctor.

Watch the video

The Future of Cancer Screening on YouTube (official channel "Jason Fung," @DrJasonFung, published November 9, 2026)

Episode guide

Chapter times come from the chapter list in the video's YouTube description. Select a time to jump to that point on YouTube.

• 0:00: Why early detection matters
• 0:42: The four stages of cancer and spread (metastasis)
• 1:24: Traditional screening tests and their risks
• 2:15: Why he says most cancer deaths are not caught by screening
• 3:30: The 2023 JAMA Internal Medicine review of screening trials
• 5:30: Estimated life gained from screening
• 6:21: Tumor size versus early spread
• 8:08: What circulating tumor DNA and a liquid biopsy are
• 8:37: Multi-cancer early detection blood tests
• 9:34: The 140,000-person trial and stage four results
• 12:08: Stage three versus stage four survival figures
• 14:07: Approval claims and his outlook

About this summary

This recap was prepared from the automatically generated YouTube transcript and the description and chapter list published with the video. Transcripts can contain errors, so names and numbers may differ from the audio. For the exact words and context, watch the video. This article is general information, not medical advice, and is not a substitute for guidance from a qualified healthcare professional.